Ronald Brazg

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023 · 590 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +6

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes

Satish K. Garg, Stuart A. Weinzimer, William V. Tamborlane et al. · Diabetes Technology & Therapeutics · 2017 · 568 citations · Full text

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

Alan Chait, Ronald Brazg, Diane L. Tribble et al. · The American Journal of Medicine · 1993 · 554 citations

Metabolic Syndrome, Pattern B, Cardiovascular Disease +14

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Julio Rosenstock, Ronald Brazg, Paula J. Andryuk et al. · Clinical Therapeutics · 2006 · 513 citations

Diabetes Management, Medicine, Pioglitazone Therapy +8

Accuracy of the 5-Day FreeStyle Navigator Continuous Glucose Monitoring System

Richard L. Weinstein, Sherwyn Schwartz, Ronald Brazg et al. · Diabetes Care · 2007 · 224 citations